Page 127 - MemoriaES-Eng

www.ciberes.org

However, the group has published in 2013 more than 50 scientific articles which

more than half are collaborative. This is because, the clinical and basic research

activity of the group 16 is mainly focused on areas of inflammation and repair,
respiratory failure and tissue hypoxia, and there is complementarily and interre-

latedness of these areas for the study of diseases such as asthma COPD, pulmo-

nary fibrosis, infections, transplant, pulmonary hypertension and sleep-disordered
breathing. For this reason, the Group is also collaborating with other Corporate

Research Programs such us COPD, Sleep Disorders and others (see publications
of the Group).

Most relevant • FreiXA X, Portillo k, PAré c, gArcíA-AYMericH J, góMeZ FP, Benet M et Al.. Echocardiogra-
phic abnormalities in patients with COPD at their first hospital admission.Eur Respir
scientific
J. 2013 Apr;41(4):784-91.
articles
• MArtíneZ-gArcíA MA, cAPote F, cAMPoS-rodrígueZ F, lloBereS P, díAZ de AtAuri MJ, SoMoZA
M, M JF, g M, S l, .. Effect of CPAP on blood pressure in patients
ASAonZáleZAcriStAnet Al
with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized
clinical trial.JAMA-J AM MED ASSOC. 2013;(310):2407-15.
ó
• P Vi, g FP, B JA, r A, A M M, r J .. Pulmonary ó
einAdoMeZArBeràoMAnngelSonteroAMíreZet Al
vascular abnormalities in chronic obstructive pulmonary disease undergoing lung

transplant.J Heart Lung Transplant. 2013 Dec;32(12):1262-9.
á

• BernStein di, kASHon M, luMMuS Zl, JoHnSon VJ, FluHArtY k, gAutrin d et Al.. CTNNA3
(α-catenin) gene variants are associated with diisocyanate asthma: a replication

study in a Caucasian worker population.Toxicol Sci. 2013 Jan;131(1):242-6.

• MonForte V, lPeZ-SncHeZ A, ZurBAno F, uSSetti P, Solé A, cASAlS c et Al.. Prophylaxis
with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant

patients does not cause changes in the lipid content of pulmonary surfactant.J Heart
Lung Transplant. 2013 Mar;32(3):313-9.

The Group has published in 2013 a paper entitled “Human mesenchymal stem
Highlights
cells overexpressing the IL-33 antagonist sST2 attenuate endotoxin-induced acute
lung injury” which resulted in a patent. This study has served us to establish new

collaborations with other groups like the group of Human Molecular Genetics from

IDIBELL, with whom we have signed a license agreement with the Basque com-
pany Histocell for the use of our patent for the treatment of acute lung diseases

with mesenchymal stem cells. These cells, administered intravenously, have the
ability to go directly to the damaged lungs, which act as a “smart drug”.

In the same line, the group has submitted a new publication for the use of these

cells in the treatment of asthma that is under review.
13
We are currently working with the Department of Molecular Physiology and chan- 20
T
nelopathies from the Universitat Pompeu Fabra for the study of the impact of OR
overexpression of the gene ORMDL3 on the susceptibility to develop occupational P
RE
asthma .
L
A
At present the group is part of a project funded by NIOSH / CDC and led by Dr. NU
David Bernstein, Division of Immunology, Allergy and Rheumatology, University N
A
of Cincinnati College of Medicine, Cincinnati, Ohio, for the study of the genetic S /
E
susceptibility to occupational asthma. This project has resulted in sevaral papers ER
published in journals of first quartile and has now begun a second phase of the B
CI
study. One of these paper has been published this year and includes two of the

groups of the asthma PCI (see publications).
127